We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+7.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$245M
AUM Growth
-$7.55M
Cap. Flow
+$6.28M
Cap. Flow %
2.56%
Top 10 Hldgs %
55.89%
Holding
90
New
18
Increased
14
Reduced
12
Closed
22

Top Buys

Rank Stock Value
1
SKYE icon
Skye Bioscience
SKYE
+$16M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$10.5M
3
ARGX icon
argenx
ARGX
+$8.8M
4
CTNM
Contineum Therapeutics
CTNM
+$6.91M
5
RZLT icon
Rezolute
RZLT
+$5.84M

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$7.66M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$6.85M
3
AXSM icon
Axsome Therapeutics
AXSM
+$6.52M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$5.22M
5
NGNE icon
Neurogene
NGNE
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 96.66%
2 Consumer Discretionary 1.68%
3 Technology 0.03%
4 Financials 0.01%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QNRX
51
Quoin Pharmaceuticals
QNRX
$8.96M
$59.8K 0.02%
2,946
+1,053
+56% +$26.8K
ONFOW icon
52
Onfolio Holdings Warrant
ONFOW
$70.1K
$49.8K 0.02%
200,000
– –
RCKTW icon
53
Rocket Pharmaceuticals Warrant
RCKTW
$214K
$44.4K 0.02%
731,561
– –
NXLIW
54
DELISTED
Nexalin Technology Inc Warrant
NXLIW
$35.7K 0.01%
105,000
– –
BNBX
55
DELISTED
BNB PLUS CORP
BNBX
$35.2K 0.01%
+115
New +$295K
VSEEW
56
VSee Health Warrant
VSEEW
$241K
$32.5K 0.01%
150,000
– –
MOBXW icon
57
Mobix Labs Warrants
MOBXW
$752K
$26.8K 0.01%
150,000
– –
NLSPW
58
DELISTED
NLS Pharmaceutics Warrant
NLSPW
$6.9K ﹤0.01%
200,000
– –
BNCWW
59
CEA Industries Inc Warrant
BNCWW
$44.7K
$3.75K ﹤0.01%
250,000
– –
CYCUW
60
Cycurion Inc Warrant
CYCUW
$265K
$3.66K ﹤0.01%
100,000
– –
CINGW icon
61
Cingulate Inc Warrants
CINGW
$26.1K
$2.92K ﹤0.01%
270,000
– –
BTMWW
62
DELISTED
Bitcoin Depot Inc Warrant
BTMWW
$2.37K ﹤0.01%
50,000
– –
NEXRW
63
Nexera Technologies Ltd Warrant
NEXRW
$41.4K
$2.2K ﹤0.01%
68,681
– –
CDTTW
64
CDT Equity Inc Warrant
CDTTW
$1.63M
$1.55K ﹤0.01%
100,000
– –
MITAW
65
DELISTED
Coliseum Acquisition Corp. Warrant
MITAW
$1.42K ﹤0.01%
28,333
– –
SRZNW icon
66
Surrozen Inc Warrant
SRZNW
$22.4K
$1.36K ﹤0.01%
82,233
– –
SLNAW
67
DELISTED
Selina Hospitality PLC Warrant
SLNAW
$1.1K ﹤0.01%
101,439
– –
TCBPW
68
DELISTED
TC BioPharm (Holdings) plc Warrants
TCBPW
$235 ﹤0.01%
18,823
– –
AQST icon
69
Aquestive Therapeutics
AQST
$481M
– –
-665,000
Closed -$2.83M
ATXS
70
DELISTED
Astria Therapeutics
ATXS
– –
-142,532
Closed -$2.01M
AZTR icon
71
Azitra
AZTR
$2.19M
– –
-2,468
Closed -$101K
BHVN icon
72
Biohaven
BHVN
$2.14B
– –
-140,000
Closed -$7.66M
GERN icon
73
CALL
Geron
GERN
$1.01B
– –
-400,000
Closed -$1.32M
GRI
74
GRI Bio
GRI
$2.66M
– –
-30
Closed -$143K
MIRM icon
75
Mirum Pharmaceuticals
MIRM
$5.77B
– –
-208,000
Closed -$5.22M
1 2
3
4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return

Altium Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Altium Capital Management held 90 positions worth $245M, down 3% from $253M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Altium Capital Management's Q2 2024 filing shows 18 new, 14 increased, 12 reduced and 22 closed positions. Its largest new stake was Skye Bioscience: 1,350,093 shares worth $10.8M. The largest sale was Biohaven, an estimated $7.66M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 86% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Altium Capital Management's largest Q2 2024 buy was Skye Bioscience: 1,350,093 shares worth $10.8M.
  • Altium Capital Management added most to Intra-Cellular Therapies Inc. in Q2 2024, an estimated $5.55M increase.
  • Altium Capital Management's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $6.52M.
  • Altium Capital Management fully exited Biohaven in Q2 2024, selling an estimated $7.66M.
  • Altium Capital Management's ten largest holdings make up 56% of its $245M portfolio in Q2 2024.
  • Altium Capital Management opened 18 new positions and closed 22 in Q2 2024.
  • Altium Capital Management's portfolio value fell 3% quarter-over-quarter to $245M.

Based on Altium Capital Management's 13F filing for Q2 2024, filed 15 Aug 2024.